Posted by Michael Wonder on 19 Dec 2020
Karyopharm announces FDA approval of Xpovio (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy
18 December 2020 - Oral Xpovio now available as a treatment option for patients with multiple myeloma as early as first relapse; significantly expands addressable patient population.
Karyopharm Therapeutics today announced that the U.S. FDA has approved Xpovio (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
